Guardant Health, Inc. (GH)
Fair bewertetFundamental
47
Kurs
$176.61
Marktkapitalisierung
$23.94B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
Natera's Signatera is the market-leading blood test for molecular residual disease after cancer surgery, competing directly with Guardant Reveal for the same oncologists and the same post-treatment monitoring reimbursement.
Tempus sells the xF+ liquid biopsy panel and tissue profiling to the same oncology practices, competing with Guardant on both therapy selection and residual disease testing.
A wholly owned Roche subsidiary whose FoundationOne Liquid CDx and FoundationOne CDx panels are the closest rivals to Guardant360 for comprehensive genomic profiling used to pick a cancer therapy.
Acquired by Abbott in March 2026 and no longer separately listed, Exact Sciences sells Cologuard and its own blood-based colorectal screening test to the same primary-care physicians Guardant targets with Shield.
Caris competes for the same oncologists' test orders with whole-exome tissue profiling and its Caris Assure blood platform, covering therapy selection and residual disease alongside Guardant.
GRAIL's Galleri is the leading multi-cancer blood screening test, competing with Guardant's Shield franchise for the same asymptomatic screening population and employer or health-system contracts.
Bilanz & Liquidität
Umsatz
$1.18B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-453M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-233M
Gesamtes Eigenkapital
$-99M
Gesamtverbindlichkeiten
$2.11B
Current Ratio
4.03
Zinsdeckungsgrad
97.65
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$197.04
Aktueller Kurs
$176.61
Sicherheitsmarge
+10.4%
Innerer-Wert-Spanne
$187.19 - $206.89
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
419.2%
P/B-Verhältnis
-
P/FCF
-
Bruttomarge
65.0%
ROIC
-23.6%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
-23.6%
WACC
13.1%
ROIC − WACC
-36.7 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (11)
- EPS shows upward trend
- Price CAGR 21.31%
- Gross Margin 65.0%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 27.9%
- Analyst Consensus 91% Buy
- Share Dilution 2.3%
- Net Margin Trend -38.3% vs -49.9%
- Piotroski F-Score 5/9
Nicht bestanden (7)
- ROIC -23.6%
- Operating Margin -39.7%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -246.6%
- Earnings Surprise avg -7.2%
Nicht verfügbar (9)
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 46 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 45 |
| Mr. Michael Bell | Chief Financial Officer | 56 |
| Dr. Darya Chudova | Chief Technology Officer | 51 |
| Mr. John G. Saia J.D. | Chief Legal Officer & Corporate Secretary | 52 |
| Mr. Andy Ament | Senior Vice President of Operations | - |
| Mr. Kumud Kalia | Chief Information Officer | 59 |
| Zarak Khurshid | Vice President of Investor Relations | - |
| Ms. Gulshan Shaver J.D. | Senior VP of Legal Affairs & Chief Compliance Officer | - |
| Ms. Jennifer Higgins | Senior Vice President of Public Affairs | - |
Prüfungsrisiko
1
Vorstandsrisiko
7
Vergütungsrisiko
7
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-19
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-30
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-30
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for GH, sourced from Markets Gazette.
- 5/20/2026POSITIVEGuardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Guardant Health has received FDA approval for an expanded use of its Guardant360 Liquid CDx test. This blood-based cancer profiling tool now offers broader diagnostic capabilities, a significant step forward in non-invasive oncology diagnostics. The expanded approval is expected to enhance the test's utility for a wider range of cancer patients and treatment decisions. For investors, this regulatory milestone signifies strong product development and market potential, potentially leading to increased adoption and revenue growth for Guardant Health.
via Markets Gazette